Aspiriant LLC’s Lam Research LRCX Stock Holding History

Aspiriant LLC’s Portfolio LRCX Stock Details LRCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$287K	Sell	1,341 -126	-9%	-$28.2K	0.01%	286
2025 Q4	$251K	Buy	+1,467	New	+$228K	0.01%	296
2024 Q2	–	Sell	-2,280	Closed	-$222K	–	313
2024 Q1	$222K	Buy	+2,280	New	+$201K	0.01%	297
2023 Q4	–	Sell	-3,810	Closed	-$239K	–	312
2023 Q3	$239K	Buy	+3,810	New	+$250K	0.01%	251

Other funds holding LRCX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aspiriant LLC's LRCX Position: Q1 2026 in Review

Aspiriant LLC reduced its Lam Research (LRCX) stake by 8.6% in Q1 2026, selling an estimated $28.2K and leaving 1,341 shares worth $287K. The position accounts for 0.01% of the portfolio, ranked #286.

Aspiriant LLC first reported a position in LRCX in Q3 2023 and has held it in 4 quarters since. 2,630 funds tracked by Wall St. Rank hold LRCX as of Q1 2026.

Aspiriant LLC held 1,341 shares of Lam Research worth $287K as of Q1 2026.
Aspiriant LLC sold 126 Lam Research shares in Q1 2026, an estimated $28.2K.
Lam Research made up 0.01% of Aspiriant LLC's portfolio in Q1 2026, its #286 holding.
Aspiriant LLC first reported a position in Lam Research in Q3 2023 and has held it in 4 quarters since.
2,630 funds tracked by Wall St. Rank held Lam Research as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.